🔍

EMCURE - Emcure Pharma

📊 NSE: EMCURE 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/13/2025 21:50

📢 Recent Corporate Announcements

Emcure Appoints Former Sun Pharma CFO C.S. Muralidharan as Independent Director

🟢 POSITIVE ⭐ 7/10

MANAGEMENT 📅 09 Mar 2026, 01:29 PM

Emcure Pharmaceuticals has appointed Mr. C.S. Muralidharan as an Independent Director for a three-year term starting April 1, 2026. Mr. Muralidharan is a seasoned professional with 40 years of experience, most notably serving as the former Group CFO of Sun Pharmaceutical Industries Limited. His extensive background includes leadership roles at other major pharmaceutical firms such as Lupin and Ranbaxy, specializing in M&A, global finance, and strategy. This high-profile board addition is expected to significantly strengthen the company's strategic governance and financial oversight.

Appointment of Mr. C.S. Muralidharan as Independent Director for a 3-year term effective April 1, 2026.
Brings 40 years of corporate experience across the pharmaceutical and hydrocarbon sectors.
Former Group CFO of Sun Pharmaceutical Industries Limited with expertise in global finance and M&A.
Previously held senior leadership positions at Lupin Limited, Ranbaxy Group, and Matrix Laboratories.

💡 Investors should view this as a positive governance move that brings top-tier industry expertise to the board; monitor for any shifts in capital allocation or M&A strategy under his guidance.

Emcure Appoints Former Sun Pharma CFO C S Muralidharan as Independent Director for 3-Year Term

🟢 POSITIVE ⭐ 7/10

MANAGEMENT 📅 09 Mar 2026, 01:08 PM

Emcure Pharmaceuticals has announced the appointment of Mr. C S Muralidharan as an Independent Director for a three-year term starting April 01, 2026. Mr. Muralidharan is a seasoned professional with over 40 years of experience, most notably serving as the former Group CFO of Sun Pharmaceutical Industries. The Board has also approved a postal ballot to seek shareholder approval for this appointment. This move is aimed at strengthening the company's board with deep industry expertise in finance, M&A, and strategy.

Appointment of Mr. C S Muralidharan as Independent Director for a 3-year term effective April 01, 2026.
Appointee brings 40 years of experience, including previous roles as Group CFO at Sun Pharma and leadership positions at Lupin and Ranbaxy.
The Board meeting was held on March 09, 2026, and concluded within 25 minutes.
Shareholder approval will be sought through a Postal Ballot via remote e-voting.
Mr. Muralidharan's expertise spans M&A, capital restructuring, and enterprise risk management.

💡 Investors should view this as a positive governance development, as the addition of a high-caliber industry veteran can enhance strategic oversight and financial discipline. No immediate action is required.

Emcure Signs Strategic Distribution Agreement with Roche for Nephrology and Transplant Care

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 02 Mar 2026, 02:49 PM

Emcure Pharmaceuticals has entered into a distribution agreement with Roche, effective April 1, 2026, to market key nephrology and transplant products in India. The portfolio includes globally recognized brands like CellCept, Mircera, and Neorecormon, targeting chronic kidney disease (CKD) and anemia management. This partnership leverages Emcure's position as the 13th largest pharma company in India to expand the reach of Roche's innovations. The move is expected to strengthen Emcure's existing market leadership in anemia management and renal care segments.

Agreement covers Roche's global brands CellCept, Mircera, and Neorecormon starting April 1, 2026
Emcure is ranked as the 13th largest pharmaceutical company in India by domestic sales as of October 2025
Partnership focuses on high-growth segments including Nephrology, Transplant Care, and Anemia management
Mircera provides a long-acting ESA therapy with dosing convenience of once every 2 to 4 weeks
The collaboration aims to utilize Emcure's distribution network across 70+ countries and deep domestic expertise

💡 Investors should view this as a significant portfolio enhancement that strengthens Emcure's competitive position in the chronic care market. Monitor the impact on margins and revenue growth in the nephrology segment starting from Q1 FY27.

Emcure Reports 16.5% Revenue Growth in 9M FY26; PAT Margins Expand 250bps to 10.4%

🟢 POSITIVE ⭐ 8/10

OTHER 📅 20 Feb 2026, 06:27 PM

Emcure Pharmaceuticals demonstrated strong financial momentum with 9M FY26 revenue growing 16.5% YoY to INR 6,734 Cr. The company achieved significant margin expansion, with PAT margins rising 250bps to 10.4% and RoCE improving to 22.7% due to operating leverage. Growth is increasingly driven by a shift towards chronic therapies in India, which now represent 38% of domestic sales, and a robust international pipeline of complex injectables and biologics. Strategic moves include the launch of Poviztra (Semaglutide) and expansion into high-growth Dermatology and Consumer OTC segments.

9M FY26 revenue reached INR 6,734 Cr, representing a 16.5% YoY growth compared to 9M FY25.
PAT margins saw a substantial 250bps increase to 10.4% since FY24, while EBITDA margins reached 19.4%.
Domestic chronic business share grew from 26.3% in March 2020 to 38% in December 2025.
Return on Capital Employed (RoCE) strengthened to 22.7% in 9M FY26, up from 19.4% in FY24.
International pipeline remains strong with 50+ products in Canada and 55+ products under development in Europe.

💡 Investors should focus on the company's successful transition toward high-margin chronic therapies and its entry into the anti-obesity market with Poviztra. The consistent margin expansion and high RoCE suggest strong operational efficiency, making it a key player to watch in the pharmaceutical sector.

Emcure Pharmaceuticals to Attend Kotak Chasing Growth Conference 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 17 Feb 2026, 08:08 PM

Emcure Pharmaceuticals Limited has scheduled its participation in the Kotak Chasing Growth Conference 2026. The event is set to take place in Mumbai on February 23 and February 24, 2026. Company officials will engage in both group and one-on-one meetings with various institutional investors. The company has clarified that no unpublished price sensitive information (UPSI) will be shared during these interactions.

Participation in the Kotak Chasing Growth Conference 2026 in Mumbai.
Event scheduled for two days: February 23 and February 24, 2026.
Meetings will include both group and one-on-one formats with institutional investors.
Compliance disclosure made under Regulation 30 of SEBI (LODR) Regulations, 2015.

💡 Investors should monitor for any investor presentations or post-conference transcripts that the company may release following the event. No immediate action is required as this is a routine investor relations activity.

Emcure Pharma Seeks Shareholder Approval for Re-appointment of Three Independent Directors

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 17 Feb 2026, 07:49 PM

Emcure Pharmaceuticals has issued a postal ballot notice to seek shareholder approval for the re-appointment of three key Independent Directors. Mr. Vijay Keshav Gokhale and Dr. Shailesh Kripalu Ayyangar are proposed for second five-year terms, while Dr. Vidya Rajiv Yeravdekar is proposed for a three-year term. A special resolution is also included to allow Dr. Ayyangar to continue his directorship beyond the age of 75. The e-voting process will conclude on March 20, 2026, with results expected by March 24, 2026.

Proposed re-appointment of Mr. Vijay Keshav Gokhale for a 5-year term effective April 16, 2026
Proposed re-appointment of Dr. Vidya Rajiv Yeravdekar for a 3-year term effective April 16, 2026
Proposed re-appointment of Dr. Shailesh Kripalu Ayyangar for a 5-year term effective June 2, 2026
Special resolution for Dr. Ayyangar to continue as Director after attaining the age of 75 years
Remote e-voting period scheduled from February 19, 2026, to March 20, 2026

💡 Investors should monitor the voting results to ensure management continuity and maintain confidence in the company's corporate governance standards. No immediate portfolio changes are necessary based on this routine administrative update.

Emcure Pharmaceuticals Q3 FY26: Revenue Up 20.4% YoY, PAT Grows 48% to ₹231 Crores

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 10 Feb 2026, 06:05 PM

Emcure Pharmaceuticals reported a strong Q3 FY26 with consolidated revenue rising 20.4% YoY to ₹2,363 crores, driven by 15.4% growth in domestic markets and 24.5% in international segments. EBITDA margins expanded to 19.5% from 18.4% YoY, despite the impact of in-licensing Sanofi's diabetes portfolio. The company reported a PAT of ₹231 crores, which grew 48% YoY, or 65% on an adjusted basis excluding a one-time ₹38 crore impact from Labour Code changes. Management highlighted the exclusive partnership with Novo Nordisk for semaglutide as a key future growth driver.

Revenue from operations grew 20.4% YoY to ₹2,363 crores, with international markets contributing ₹1,338 crores.
EBITDA increased 27.2% YoY to ₹460 crores, reflecting strong operating leverage and productivity gains.
Europe business recorded a significant 29.6% YoY growth to ₹464 crores, aided by the Manx acquisition and base business ramp-up.
Domestic business grew 15.4% YoY to ₹1,025 crores, led by chronic therapies like Cardio-Diabeto and Oncology.
Net debt stood at ₹1,203 crores as of Q3 FY26, primarily due to the payout for the Zuventus minority stake.

💡 Investors should focus on the company's margin expansion trajectory and the successful commercialization of the Novo Nordisk partnership. The strong growth in international markets and positioning in biologics make it a solid pick in the mid-cap pharma space.

Emcure Reports Fire at Pune Plant; Operations Disrupted for 5-7 Days

🔵 WATCH ⭐ 4/10

OTHER 📅 07 Feb 2026, 09:56 PM

Emcure Pharmaceuticals reported a fire incident at the utility block of its Hinjawadi, Pune manufacturing plant (Plant I) on February 7, 2026. While the fire was successfully controlled and no casualties were reported, operations at the facility are temporarily disrupted for an estimated 5 to 7 days. The company has stated that the incident is unlikely to have a material impact on its overall financial performance. Adequate insurance coverage is in place, and the company is currently assessing the specific quantum of damage.

Fire occurred at the utility block of the Hinjawadi, Pune manufacturing plant on February 7, 2026
Plant operations are expected to be disrupted for a period of 5 to 7 days
Management confirms zero human injuries or casualties resulting from the incident
Company expects no material impact on financials and maintains adequate insurance coverage
Insurance company has been notified and damage assessment is currently underway

💡 Investors should monitor if the operational disruption extends beyond the estimated 7-day window. Since no material financial impact is expected and the plant is insured, this remains a minor operational update.

Emcure Pharmaceuticals Releases Q3 FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 04 Feb 2026, 06:40 PM

Emcure Pharmaceuticals has officially released the audio recording of its Q3 FY26 earnings conference call held on February 04, 2026. This filing follows the company's prior notification to the exchanges on January 22, 2026. The recording provides a detailed account of the management's discussion regarding the company's financial performance and strategic direction. Investors can access the full audio via the link provided on the company's investor relations website.

Audio recording of Q3 FY26 earnings call made available on February 04, 2026
Compliance with Regulation 30 of SEBI Listing Obligations and Disclosure Requirements
Follow-up to the initial earnings call intimation dated January 22, 2026
Direct link provided for investor access to management commentary

💡 Investors should review the audio recording to understand the management's perspective on Q3 results and future growth drivers. This is a routine disclosure and does not necessitate immediate portfolio changes.

Emcure Pharmaceuticals Updates Key Managerial Personnel for Materiality Disclosures

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 04 Feb 2026, 03:06 PM

Emcure Pharmaceuticals has updated its list of Key Managerial Personnel (KMP) authorized to determine the materiality of events and disclose information to stock exchanges under SEBI Regulation 30(5). This update follows the appointment of Ms. Amruta Jana Yangalwar as the new Company Secretary and Compliance Officer. The authorized group now includes the CEO, Whole-time Director, CFO, and the new CS. This is a routine administrative update to ensure continued compliance with corporate governance standards.

Updated KMP list includes MD & CEO Mr. Satish Mehta and Whole-time Director Mr. Sunil Mehta
CFO Mr. Tajuddin Shaikh and newly appointed CS Ms. Amruta Jana Yangalwar are authorized for disclosures
The update follows the appointment of a new Company Secretary and Compliance Officer (ACS 25687)
Disclosure is made in compliance with Regulation 30(5) of SEBI (LODR) Regulations, 2015

💡 No action is required as this is a routine regulatory update regarding the company's compliance and disclosure team. It does not impact the company's financial performance or business operations.

Emcure Pharmaceuticals Re-appoints Three Independent Directors for Second Terms

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 04 Feb 2026, 02:22 PM

Emcure Pharmaceuticals has approved the re-appointment of three key Independent Directors to its Board, ensuring continuity in corporate governance. Dr. Shailesh Kripalu Ayyangar and Mr. Vijay Keshav Gokhale have been re-appointed for five-year terms, while Dr. Vidya Rajiv Yeravdekar has been re-appointed for three years. These appointments are for second consecutive terms and are subject to shareholder approval. The directors bring significant experience from the pharmaceutical, diplomatic, and educational sectors respectively.

Dr. Shailesh Kripalu Ayyangar re-appointed for a 5-year term effective June 02, 2026
Mr. Vijay Keshav Gokhale (former Foreign Secretary) re-appointed for a 5-year term effective April 16, 2026
Dr. Vidya Rajiv Yeravdekar re-appointed for a 3-year term effective April 16, 2026
All three directors have been associated with the company since April 16, 2021
Re-appointments ensure board continuity and maintain high-quality independent oversight

💡 Investors should view this as a positive sign of board stability and continuity of oversight. No immediate action is required as these are routine re-appointments of highly experienced professionals.

Emcure Appoints Amruta Jana Yangalwar as Company Secretary & Compliance Officer

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 04 Feb 2026, 02:08 PM

Emcure Pharmaceuticals has appointed Ms. Amruta Jana Yangalwar as the new Company Secretary and Compliance Officer, effective February 4, 2026. Designated as a Key Managerial Personnel (KMP), she brings over 16 years of post-qualification experience in corporate secretarial practice and regulatory compliance. The appointment was approved by the Board of Directors following a meeting on the same day. This transition is part of the company's routine governance and compliance management.

Ms. Amruta Jana Yangalwar appointed as Company Secretary and Compliance Officer effective Feb 4, 2026
Appointee has over 16 years of experience in corporate secretarial practice and regulatory compliance
Designated as Key Managerial Personnel (KMP) under SEBI Listing Regulations
Board meeting for the approval concluded in 35 minutes, between 12:40 PM and 1:15 PM IST

💡 This is a routine administrative appointment to ensure regulatory compliance. No immediate action is required as it does not impact the company's financial performance or business strategy.

Emcure Pharma Q3 PAT Jumps 48% YoY to ₹2,314 Million; Revenue Up 20%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 04 Feb 2026, 01:34 PM

Emcure Pharmaceuticals reported a strong performance for the quarter ended December 31, 2025, with consolidated revenue growing 20.4% YoY to ₹23,634.78 million. Net profit for the quarter surged by 48.2% YoY to ₹2,313.70 million, driven by robust operational growth and improved margins. For the nine-month period of FY26, the company achieved a revenue of ₹67,338.37 million and a PAT of ₹6,975.33 million. Additionally, the board approved the re-appointment of three key independent directors and appointed a new Company Secretary to strengthen corporate governance.

Consolidated Revenue from operations grew 20.4% YoY to ₹23,634.78 million in Q3 FY26.
Net Profit (PAT) increased significantly by 48.2% YoY to ₹2,313.70 million from ₹1,560.91 million.
Basic Earnings Per Share (EPS) improved to ₹12.16 in Q3 FY26 compared to ₹8.12 in Q3 FY25.
9M FY26 total income reached ₹67,425.09 million, up from ₹58,425.60 million in the previous year.
Board approved the re-appointment of Independent Directors Dr. Shailesh Ayyangar, Mr. Vijay Gokhale, and Dr. Vidya Yeravdekar.

💡 The strong double-digit growth in both top-line and bottom-line indicates healthy operational momentum and efficiency. Investors should maintain a positive outlook while monitoring the company's ability to maintain these margins in upcoming quarters.

Emcure Pharmaceuticals Schedules Q3 FY26 Earnings Call for February 4, 2026

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 22 Jan 2026, 04:20 PM

Emcure Pharmaceuticals Limited has announced its earnings call for the third quarter and nine months ended December 31, 2025, scheduled for February 4, 2026, at 4:00 PM IST. The management will discuss the company's unaudited standalone and consolidated financial performance during this session. The call includes universal access numbers and international toll-free options for global investors. Audio recordings and transcripts will be made available on the company's website following the event.

Earnings call scheduled for February 4, 2026, at 4:00 PM IST to discuss Q3 FY26 results.
Covers financial performance for the quarter and nine-month period ending December 31, 2025.
Universal dial-in numbers provided are +91 22 6280 1220 and +91 22 7115 8122.
International toll-free numbers available for USA, UK, Singapore, and Hong Kong.

💡 Investors should mark the date to gain insights into the company's quarterly performance and management's future outlook. Review the financial results once published on the exchange prior to the call.

Emcure Pharmaceuticals Submits Quarterly Compliance Certificate for Dec 2025

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 07 Jan 2026, 01:28 PM

Emcure Pharmaceuticals has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The document confirms that the company's Registrar and Share Transfer Agent (RTA), MUFG Intime India Private Limited, has processed all dematerialization requests for the quarter ended December 31, 2025. This filing ensures that physical share certificates were verified, cancelled, and substituted with the depository's name in the register of members within the mandated timelines. This is a standard administrative procedure required for all listed companies in India to maintain accurate electronic shareholding records.

Compliance certificate issued for the quarter ended December 31, 2025.
Confirmation provided by MUFG Intime India Private Limited (formerly Link Intime India Private Limited).
Securities received for dematerialization were confirmed and listed on the stock exchanges.
Physical certificates were mutilated and cancelled after due verification within prescribed timelines.

💡 No action is required as this is a routine regulatory filing. Investors should continue to monitor the company's upcoming quarterly financial results for material performance updates.

View All EMCURE Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total revenue grew 18.6% YoY to INR 7,896 Cr in FY25. Domestic revenue grew 16.4% YoY to INR 3,660 Cr, while International revenue rose 20.5% YoY to INR 4,236 Cr. In Q2 FY26, total revenue reached INR 2,270 Cr, a 13.4% YoY increase, with the domestic business growing 10.6% to INR 1,031 Cr.

Geographic Revenue Split

In FY25, the domestic market contributed 47% of total revenue, while international markets accounted for 54%. Within international markets for Q2 FY26, Europe grew 22.7% YoY to INR 444 Cr, Canada grew 17.5% YoY to INR 348 Cr, and Emerging Markets grew 8.6% YoY to INR 446 Cr.

Profitability Margins

Gross Profit for FY25 was INR 4,749.4 Cr (60.1% margin), up 13.5% YoY. PAT grew 34.1% YoY to INR 707.5 Cr in FY25, with PAT margins improving 250 bps to 9.0% from 7.9% in FY24. Q2 FY26 PAT was INR 251 Cr, a 24% YoY increase.

EBITDA Margin

EBITDA margin stood at 18.6% for FY25 (INR 1,468.9 Cr), up from 18.5% in FY24. Margins expanded to 19.3% in Q2 FY26 and 19.84% in Q1 FY26, driven by operating leverage, productivity gains, and a shift toward chronic therapies.

Capital Expenditure

The company has planned an annual capex of INR 350-400 Cr for FY26 to support operational maintenance and capacity expansion. Additionally, it spent INR 725 Cr in FY26 to acquire the remaining 20.42% stake in its subsidiary, Zuventus Healthcare Ltd.

Credit Rating & Borrowing

CRISIL reaffirmed 'CRISIL AA-/Positive/A1+' and CARE assigned 'CARE AA-; Positive'. Interest coverage improved significantly to 9.03x in FY25 from 5.4x in FY24 due to debt reduction. Interest cost for Q2 FY26 was INR 33 Cr.

⚙️ Operational Drivers

Raw Materials

The documents mention APIs (Active Pharmaceutical Ingredients) and formulations as core components, but specific chemical names and their percentage of total cost are not disclosed.

Capacity Expansion

Planned capex of INR 350-400 Cr for FY26 is dedicated to capacity expansion and maintenance. Current installed capacity in units or MT is not specified.

Raw Material Costs

Gross margins stood at 60.8% in Q2 FY26, implying raw material and direct production costs are approximately 39.2% of revenue. Procurement strategies include in-house manufacturing for complex injectables to control the supply chain.

Manufacturing Efficiency

Efficiency is being driven by improved Medical Representative (MR) productivity and better utilization of in-house manufacturing for complex injectables and biosimilars.

📈 Strategic Growth

Expected Growth Rate

14-15%

Growth Strategy

Growth will be achieved through a 5-year plan focusing on 'good to great' transition, including strategic in-licensing (e.g., Sanofi portfolio), expanding the chronic therapy mix, scaling complex injectables and biosimilars in emerging markets, and accretive M&A such as the Mantra Pharma and Zuventus acquisitions.

Products & Services

Pharmaceutical formulations, biologics, APIs, complex injectables, biosimilars, and consumer wellness products.

Brand Portfolio

Arth, Galact, Mantra, Zuventus, and Sanofi (in-licensed products).

New Products/Services

Entry into consumer wellness via Arth and Galact brands; launch of in-licensed Sanofi products across various segments; and a pipeline of complex injectables and biosimilars.

Market Expansion

Expansion into the consumer wellness space and scaling up the international business, particularly in Canada, Europe, and Emerging Markets through differentiated products.

Market Share & Ranking

Emcure is a top 15 pharmaceutical company in India with a domestic market share of 2.18% as of March 2025.

Strategic Alliances

Strategic in-licensing arrangement with Sanofi to promote and distribute their products in India; partnership with Mantra Pharma Inc. in Canada.

🌍 External Factors

Industry Trends

The industry is shifting toward chronic therapies and complex generics. Emcure is positioning itself by increasing its chronic portfolio and investing in biosimilars to outpace industry growth.

Competitive Landscape

Operates in a highly competitive environment against both domestic and international generic players, facing constant pricing pressure.

Competitive Moat

Moat is built on a top 15 domestic ranking, a 2.18% market share, and a differentiated product pipeline. Sustainability is supported by high entry barriers in complex injectables and long-term MNC in-licensing partnerships.

Macro Economic Sensitivity

Sensitive to government healthcare policies and DPCO pricing regulations in India, which directly affect revenue from the domestic formulations market.

Consumer Behavior

Increasing demand for chronic disease management and consumer wellness products is driving the company's shift in therapy mix.

Geopolitical Risks

Minimal exposure to the US market (safeguarding from US tariff risks), but faces regulatory risks in other regulated markets like Europe and Canada.

⚖️ Regulatory & Governance

Industry Regulations

Subject to Drug Price Control Order (DPCO) in India and stringent manufacturing standards/safety protocols globally. Compliance is critical to avoid product withdrawals or regulatory actions.

Environmental Compliance

The company maintains a health and safety policy to comply with legislative requirements and certifications, though specific ESG costs in INR were not disclosed.

Taxation Policy Impact

The effective tax rate was 26% for Q2 FY26.

Legal Contingencies

Resolution of HDT and anti-trust lawsuits in 2024 has reduced uncertainty; however, the company remains exposed to ongoing legal and regulatory risks inherent in the regulated generics business.

⚠️ Risk Analysis

Key Uncertainties

Potential for sizeable debt-funded acquisitions to alter debt protection metrics; regulatory changes in international markets could impact 54% of revenue.